Singular Genomics Systems, Inc. provided unaudited revenue guidance for the fourth quarter of 2023. For the quarter, the company revenue is expected to be approximately $1.0 million, representing growth of approximately 31% compared to $765,000 during the fourth quarter of 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.375 USD | +2.82% | -1.57% | -18.50% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.50% | 27.02M | |
+48.64% | 54.63B | |
-6.44% | 39.92B | |
+37.07% | 38.82B | |
+14.28% | 26.86B | |
-11.17% | 26.22B | |
-21.40% | 18.78B | |
+25.64% | 12.21B | |
+0.96% | 12.16B | |
+27.04% | 11.94B |
- Stock Market
- Equities
- OMIC Stock
- News Singular Genomics Systems, Inc.
- Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023